The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
Abstract
OBJECTIVE: To determine the degree to which alpha-glucosidase inhibitors, with their unique mode of action primarily reducing postprandial hyperglycemia, offer an additional therapeutic approach in the long-term treatment of type 2 diabetes. RESEARCH DESIGN AND METHODS: We studied 1,946 patients (63% men) who were previously enrolled in the U.K. Prospective Diabetes Study (UKPDS). The patients were randomized to acarbose (n = 973), titrating to a maximum dose of 100 mg three times per day, or to matching placebo (n = 973). Mean +/- SD age was 59 +/- 9 years, body weight 84 +/- 17 kg, diabetes duration 7.6 +/- 2.9 years, median (interquartile range) HbA1c 7.9% (6.7-9.5), and fasting plasma glucose (FPG) 8.7 mmol/l (6.8-11.1). Fourteen percent of patients were treated with diet alone, 52% with monotherapy, and 34% with combined therapy. Patients were monitored in UKPDS clinics every 4 months for 3 years. The main outcome measures were HbA1c, FPG, body weight, compliance with study medication, incidence of side effects, and frequency of major clinical events. RESULTS: At 3 years, a lower proportion of patients were taking acarbose compared with placebo (39 vs. 58%, P < 0.0001), the main reasons for noncompliance being flatulence (30 vs. 12%, P < 0.0001) and diarrhea (16 vs. 8%, P < 0.05). Analysis by intention to treat showed that patients allocated to acarbose, compared with placebo, had 0.2% significantly lower median HbA1c at 3 years (P < 0.001). In patients remaining on their allocated therapy, the HbA1c difference at 3 years (309 acarbose, 470 placebo) was 0.5% lower median HbA1c (8.1 vs. 8.6%, P < 0.0001). Acarbose appeared to be equally efficacious when given in addition to diet alone; in addition to monotherapy with a sulfonylurea, metformin, or insulin; or in combination with more complex treatment regimens. No significant differences were seen in FPG, body weight, incidence of hypoglycemia, or frequency of major clinical events. CONCLUSIONS: Acarbose significantly improved glycemic control over 3 years in patients with established type 2 diabetes, irrespective of concomitant therapy for diabetes. Careful titration of acarbose is needed in view of the increased noncompliance rate seen secondary to the known side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of Insulin Resistance and Beta-Cell Function: The HOMA and CIGMA Approach
Turner, R. C., Lévy, J., Rudenski, A. S., Hammersley, M., & Page, R. C. (2015) · Frontiers in diabetes · doi:10.1159/000422658 · Cited by 18
Self-citation
Cited by
Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Low–Glycemic Index Diets in the Management of Diabetes
Brand-Miller, J., Hayne, S., Petocz, P., & Colagiuri, S. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2261 · Cited by 951
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., van de Lisdonk, E. H., Rutten, G. E., & van Weel, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.154 · Cited by 690
Inhibitory effect of pine extract on α-glucosidase activity and postprandial hyperglycemia
Kim, Y.-M., Jeong, Y.-K., Wang, M.-H., Lee, W.-Y., & Rhee, H.-I. (2005) · Nutrition · doi:10.1016/j.nut.2004.10.014 · Cited by 531
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
Low glycaemic index, or low glycaemic load, diets for diabetes mellitus
Thomas, D., & Elliott, E. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006296.pub2 · Cited by 362
Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003639.pub2 · Cited by 335
A novel α-glucosidase inhibitor from pine bark
Kim, Y.-M., Wang, M.-H., & Rhee, H.-I. (2004) · Carbohydrate Research · doi:10.1016/j.carres.2003.11.005 · Cited by 325
Holman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30309-1 · Cited by 323
Self-citationPotent α-glucosidase inhibitors purified from the red alga Grateloupia elliptica
Kim, K. Y., Nam, K. A., Kurihara, H., & Kim, S. M. (2008) · Phytochemistry · doi:10.1016/j.phytochem.2008.09.007 · Cited by 323
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Low-glycemic index diets as an intervention for diabetes: a systematic review and meta-analysis
Zafar, M. I., Mills, K. E., Zheng, J., Regmi, A., Hu, S. Q., Gou, L., & Chen, L.-L. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz149 · Cited by 245
The use of low-glycaemic index diets in diabetes control
Thomas, D. E., & Elliott, E. J. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510001534 · Cited by 225
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2006) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd002967.pub2 · Cited by 163
Ryu, H. W., Cho, J. K., Curtis-Long, M. J., Yuk, H. J., Kim, Y. S., Jung, S., Kim, Y. S., Lee, B. W., & Park, K. H. (2011) · Phytochemistry · doi:10.1016/j.phytochem.2011.08.007 · Cited by 161
Evidence-based practice guideline for the treatment for diabetes in Japan 2013
Tajima, N., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Fujimoto, K., Sakamoto, M., & Haneda, M. (2015) · Diabetology International · doi:10.1007/s13340-015-0206-2 · Cited by 154
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Acarbose: oral antidiabetes drug with additional cardiovascular benefits
Hanefeld, M., & Schaper, F. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.2.153 · Cited by 87
Postchallenge Hyperglycemia in a National Sample of U.S. Adults With Type 2 Diabetes
Erlinger, T. P., & Brancati, F. L. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1734 · Cited by 83
Øhrstrøm, C. C., Worm, D., Højager, A., Andersen, D., Holst, J. J., Kielgast, U. L., & Hansen, D. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13796 · Cited by 72
Hücking, K., Kostic, Z., Pox, C., Ritzel, R., Holst, J. J., Schmiegel, W., & Nauck, M. A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01451.x · Cited by 57
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
Yang, H. K., Lee, S.-H., Shin, J., Choi, Y.-H., Ahn, Y.-B., Lee, B.-W., Rhee, E. J., Min, K. W., & Yoon, K.-H. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0054 · Cited by 25
Metadata
- Authors
- Holman, R. R., Cull, C. A., & Turner, R. C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1999-06-01
- Volume
- 22
- Issue
- 6
- Pages
- 960-964
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2100076167
- Cited by
- 449
- References
- 1
- FWCI
- 11.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.